# US 2021/0171567 A1 · Oxysterols and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171567 A1
- Document ID: US20210171567A1
- Status: Published application
- Kind: A1
- Application number: 16/930,047
- Filed: 2020-07-15
- Published: 2021-06-10
- Earliest claimed: 2016-05-06
- Assignees: Sage Therapeutics, Inc.
- Applicants: Sage Therapeutics, Inc.
- Inventors: Gabriel Martinez Botella; Boyd L. Harrison; Albert Jean Robichaud; Francesco G. Salituro
- Web page: https://patentgrep.com/patent/US20210171567A1

## CPC

- C07J 9/00: Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J 9/005: {containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07J: STEROIDS (seco-steroids C07C)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Compounds are provided according to Formula (III): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R5, and n are as defined herein, and at least one hydrogen is replaced with a deuterium. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

## Claims

### Claim 1

A pharmaceutical composition comprising a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is hydrogen or deuterium;
each of R2 and R3 is independently deuterium or —C1-6 alkyl;
R4 is hydrogen or deuterium;
R5 is absent, hydrogen, or deuterium;
n is 1 or 2;
represents a single or double bond, wherein when one is a double bond, the other is a single bond and R5 is absent; and
at least one of R1, R2, R3, R4, or R5 is deuterium; and
a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein R1 is hydrogen.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein R1 is deuterium.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein R1 and R2 are deuterium.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein one of R2 and R3 is deuterium and the other of R2 and R3 is C1-6 alkyl.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein each of R2 and R3 is independently —C1-6 alkyl.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein each of R2 and R3 is independently isopropyl, —CH3, or —CF3.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein R4 is hydrogen.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein n is 1.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein n is 2.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein represents a single bond.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein the compound of Formula (I) is a compound of Formula (I-A):
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein the compound of Formula (I) is a compound of Formula (I-B):
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein the compound of Formula (I) is a compound of Formula (I-C):
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein the compound of Formula (I) is a compound of Formula (I-D):
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein the compound of Formula (I) is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A method of inducing sedation or anesthesia comprising administering to a subject an effective amount of the pharmaceutical composition of claim 1.

### Claim 19 (depends on 1)

A method for treating or preventing a disorder described herein, comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 1.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the disorder is a gastrointestinal (GI) disorder, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), structural disorders affecting the GI, anal disorders, colon polyps, cancer, or colitis.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the disorder is inflammatory bowel disease.

### Claim 22 (depends on 19)

The method according to claim 19, wherein the disorder is cancer, diabetes, or a sterol synthesis disorder.

### Claim 23 (depends on 1)

A method for treating or preventing a CNS-related condition comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 1.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the CNS-related condition is an adjustment disorder, anxiety disorder, cognitive disorder, dissociative disorder, eating disorder, mood disorder, schizophrenia or other psychotic disorder, sleep disorder, substance-related disorder, personality disorder, autism spectrum disorders, neurodevelopmental disorder, multiple sclerosis, sterol synthesis disorders, pain, encephalopathy secondary to a medical condition, seizure disorder, stroke, traumatic brain injury, movement disorder, vision impairment, hearing loss, or tinnitus.

### Claim 25 (depends on 23)

The method according to claim 23, wherein the disorder is sterol synthesis disorder.

### Claim 26 (depends on 1)

A method for treating or preventing Smith-Lemli-Opitz Syndrome (SLOS), Desmosterolosis, Sitosterolemia, Cerebrotendinous xanthomatosis (CTX), Mevalonate Kinase Deficiency Syndromes (MKD), SC4MOL gene mutation (SMO Deficiency), Niemann-Pick disease, or autism disorders associated with phenylketonuria, comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 1.
